Immunovant: Upgraded To 'Buy' Because Of IMVT-1402's Broad Potential
Immunovant, Inc. has been upgraded to a 'Buy' rating due to the promising potential of its drug IMVT-1402. This drug has shown encouraging results in treating difficult-to-treat rheumatoid arthritis (RA), with 72.7% of patients responding positively by week 16. The company also boasts a strong balance sheet, providing confidence in its financial stability moving forward.
- ▪Immunovant's focus has shifted from batoclimab to IMVT-1402.
- ▪IMVT-1402 has demonstrated a 72.7% positive response rate in hard-to-treat RA patients by week 16.
- ▪The company has a solid balance sheet, ensuring financial stability.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4908492-immunovant-upgraded-to-buy-because-of-imvt-1402s-broad-potential"},"author":{"@type":"Person","name":"Myriam…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
